Microbot Medical’s Strategic Growth and LIBERTY System’s Market Readiness Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Microbot Medical (MBOT – Research Report), retaining the price target of $9.00.

Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Microbot Medical’s strategic positioning and potential for growth. The company is gearing up for the anticipated U.S. launch of its LIBERTY endovascular robotic system in the third quarter of 2025, with its 510(k) premarket notification currently under FDA review. This preparation includes expanding their commercial team, which positions them well for a successful market entry once clearance is obtained.
Moreover, the LIBERTY system has demonstrated impressive results in pivotal trials, achieving a 100% success rate in robotic navigation without any adverse device events. This, coupled with a significant reduction in radiation exposure, underscores the system’s clinical efficacy and safety. Financially, Microbot Medical appears stable, with sufficient cash reserves projected to last into 2027, supporting their operational and commercial activities. These factors collectively contribute to the reiterated Buy rating and a price target of $9 per share.

Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Vanda, and Anavex Life Sciences. According to TipRanks, Selvaraju has an average return of 16.5% and a 48.28% success rate on recommended stocks.